Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster

Emerg Microbes Infect. 2021 Dec;10(1):797-809. doi: 10.1080/22221751.2021.1913974.

Abstract

Reinfections with SARS-CoV-2 have already been documented in humans, although its real incidence is currently unknown. Besides having a great impact on public health, this phenomenon raises the question of immunity generated by a single infection is sufficient to provide sterilizing/protective immunity to a subsequent SARS-CoV-2 re-exposure. The Golden Syrian hamster is a manageable animal model to explore immunological mechanisms able to counteract COVID-19, as it recapitulates pathological aspects of mild to moderately affected patients. Here, we report that SARS-CoV-2-inoculated hamsters resolve infection in the upper and lower respiratory tracts within seven days upon inoculation with the Cat01 (G614) SARS-CoV-2 isolate. Three weeks after the primary challenge, and despite high titres of neutralizing antibodies, half of the animals were susceptible to reinfection by both identical (Cat01, G614) and variant (WA/1, D614) SARS-CoV-2 isolates. However, upon re-inoculation, only nasal tissues were transiently infected with much lower viral replication than those observed after the first inoculation. These data indicate that a primary SARS-CoV-2 infection is not sufficient to elicit a sterilizing immunity in hamster models but protects against lung disease.

Keywords: SARS-CoV-2; animal model; golden Syrian hamster; infection; protection; re-infection; viral variants.

MeSH terms

  • Animals
  • Antibodies, Neutralizing / immunology
  • Antibodies, Viral / immunology
  • COVID-19 / diagnosis
  • COVID-19 / immunology*
  • COVID-19 / pathology
  • COVID-19 / virology*
  • Cell Line
  • Cricetinae
  • Disease Models, Animal
  • Female
  • Host-Pathogen Interactions / immunology*
  • Humans
  • Immunity, Humoral
  • Immunohistochemistry
  • Male
  • Neutralization Tests
  • Reinfection / virology*
  • SARS-CoV-2 / genetics
  • SARS-CoV-2 / immunology*
  • SARS-CoV-2 / isolation & purification*
  • Viral Load
  • Virus Replication

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral

Grants and funding

The CBIG Consortium (constituted by IRTA-CReSA, BSC, & IrsiCaixa) is supported by Grifols pharmaceutical. The authors also acknowledge the crowdfunding initiative of https://www.yomecorono.com.